anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a pigment which has excellent resistance to water, solvents, oxidation and light and safety and gives a clear color, by bringing a porous alumina contg. an anion into contact with an org. dye soln. and then sealing pores. CONSTITUTION:A porous alumina contg. 0.1mol/kg or more of an anion is brought into contact with an org. dye soln. to enclose a dye in pores, and the pores contg. the dye are sealed. Any of porous alumina contg. 0.1mol/kg or more of an anion and having pores capable of enclosing an org. dye molecule therein may be used, but one having a specific surface area of 10m<2>/g or above is preferred to enclose the dye molecule therein. As the anion, chloride and sulfate ions are particularly preferred.
INTRODUCTION: Anorexia Nervosa (AN) is a psycho-socio-biological disease characterized by severe weight loss as result of dieting and hyperactivity. Effective treatments are scarce, despite its significant prevalence and mortality. AN patients show lower basal insulin levels and increased metabolic clearance, leading to weight loss, cognitive deficits, and hormonal imbalances. Low-dose polymer insulin could potentially reverse these effects by restoring brain function, reducing fear of weight gain, encouraging food intake, and restoring fat depots. This study evaluates an insulin delivery system designed for sustained release and AN treatment.
METHODS: AN-like model was established through dietary restriction (DR). On days 1-25, mice were on DR, and on days 26-31 they were on ad libitum regimen. An insulin-loaded delivery system was administered subcutaneously (1% w/w insulin). The impact of insulin treatment on gene expression in the hippocampus (cognition, regulation of stress, neurogenesis) and hypothalamus (eating behavior, mood) was assessed. Behavioral assays were conducted to evaluate motor activity and cognitive function.
RESULTS: The delivery system demonstrated sustained insulin release, maintaining therapeutic plasma levels. Diet restriction mice treated with the insulin delivery system showed body weight restoration. Gene expression analysis revealed enhanced expression of CB1 and CB2 genes associated with improved eating behavior and cognition, while POMC expression was reduced. Insulin-polymer treatment restored cognitive function and decreased hyperactivity in the AN-like model.
CONCLUSION: The PSA-RA-based insulin delivery system effectively restores metabolic balance, body weight, and cognitive function in the AN model. Its ability to steadily release insulin makes it a promising candidate for AN treatment."
ESP block (Group ESP) will be performed in the preoperative block room. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. From superior to inferior; trapezius (upper), rhomboideus major (middle), erector spinae (lower) muscles will be visualized on the hyperechoic transverse process. The 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be inserted in a cranio caudal direction and then for correction of the needle 5 ml normal saline solution will be enjected into the erector spina muscle fascia (figure). Following confirmation of the correct position of the needle, a dose of 20 ml %0.25 bupivacaine was administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine).
The UH3 study is considered a Stage II research according to the NIH Stage Model and builds directly upon the rigor of our previous formative research work, including a study supported by R21 DE016483-02. The R21 study tested the effectiveness of an autonomy-supportive videotaped oral health message informed by the self-determination theory (SDT) as a preventive behavioral approach for ECC among WIC-enrolled 12- to 49-month old children and their mothers. This grant was exploratory in nature and did not allow our research team to have a control group. In order to test the study intervention against the standard dental educational brochures, funding was obtained through the University of Iowa (UI) College of Dentistry to recruit participants to a control group. This concurrent control group was recruited to facilitate future study planning, including estimation of effect sizes. Results from the R21 study provided evidence of the effectiveness of the SDT-framed autonomy-supportive videotaped intervention in changing several oral health behaviors for ECC prevention: increased children's daily brushing habits, use of fluoridated toothpaste, mother's lifting their children's lip to look for early signs of ECC, and compliance with the consumption of no more than 4 ounces of 100% juice daily. Additional behavioral changes included decreased nighttime feeding other than water, and reduced number of daily cariogenic snacks consumed. The future proposed UH3 study will improve upon our previous investigations in two ways. First, the investigators will enhance the expected effectiveness of our experimental manipulation by creating and implementing a more research-informed age targeted oral health message. Second, the UH3 mechanism will allow us to enhance our capacity to assess the effectiveness of the SDT-derived videotaped oral health message compared to a control group with an optimal, sufficiently powered sample size. The investigators believe they have a strong scientific foundation for this project based on the rigor of our prior research efforts. Our approach will have a broader impact in that it tests a low-cost behavioral intervention that can be used in WIC clinics and other public health settings across the nation. As such, the use of evidence-based autonomy-supportive messages could efficiently disseminate an important and effective health promotion message that has great generalizability and the potential to greatly reduce the burden of ECC among some of the most vulnerable populations.
A kind of compound Chinese cassia tree capsule and preparation method thereof, belongs to medical technical field. Chinese cassia tree compound capsule of the present invention utilizes She Gan for primary raw material, and the auxiliary perilla seed, radish seed, tribulus terrestris, hoveniae semoveniae semen of joining forms. The composite mutual promotion of multiple medicinal material improves drug effect, supplements the deficiency of single medicinal material. Products taste is good, has a significant effect, and long shelf-life. The sub-compound capsule production technology of She Gan of the present invention is scientific and effective, easy easy operating. Characteristic for different pharmaceutical raw material is purified, and the active ingredient retaining to greatest extent can meet different consumers' health demand.
The recommended dosage of gentamicin injection for patients with serious infections and normal renal function is 3 mg/kg/day, administered in three equal doses every eight hours (Table 3). 

For patients with life-threatening infections, dosages up to 5 mg/kg/day may be administered in three or four equal doses. This dosage should be reduced to 3 mg/kg/day as soon as clinically indicated (Table 3). 

It is desirable to measure both peak and trough serum concentrations of gentamicin to determine the adequacy and safety of the dosage. When such measurements are feasible, they should be carried out periodically during therapy to assure adequate but not excessive drug levels. For example, the peak concentration (at 30 to 60 minutes after IM injection) is expected to be in the range of 4 to 6 mcg/mL. When monitoring peak concentrations after IM or IV administration, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring trough concentrations (just prior to the next dose), dosage should be adjusted so that levels above 2 mcg/mL are avoided. Determination of the adequacy of a serum level for a particular patient must take into consideration the susceptibility of the causative organism, the severity of the infection and the status of the patient's host-defense mechanisms. 

In patients with extensive burns, altered pharmacokinetics may result in reduced serum concentrations of aminoglycosides. In such patients treated with gentamicin, measurement of serum concentrations is recommended as a basis for dosage adjustment.
BACKGROUND: Risk of recurrence from primary ER+ breast cancer continues for at least 20 years. We aimed to identify clinical and molecular features associated with risk of recurrence after 10 years.
METHODS: ER+ breast cancers from patients with and without recurrence were analysed with the BC360 NanoString Panel and an 87 gene targeted-exome panel. Frequency of clinical, pathologic and molecular characteristics was compared between cases (recurred between 10 and 20 years) and controls (no recurrence by 20 years) in the Very Late Recurrence (VLR) cohort. Analogous data from METABRIC were examined to confirm or refute findings.
RESULTS: VLR cases had larger tumours and higher node positivity. Both VLR and METABRIC cases had higher clinical treatment score at 5 years (CTS5). There was a trend for fewer GATA3 mutations in cases in both VLR and METABRIC but no statistically significant differences in mutation frequency. Cell cycle and proliferation genes were strongly expressed in VLR cases. Immune-related genes and cell cycle inhibitors were highly expressed in controls. Neither of these changes were significant after correction for multiple testing.
CONCLUSIONS: Clinicopathologic features are prognostic beyond 10 years. Conversely, molecular features, such as copy number alterations, TP53 mutations and intrinsic subtype which have early prognostic significance, have little prognostic value after 10 years.
FIELD: organic chemistry, biochemistry. SUBSTANCE: invention proposes derivatives of quinazolinone of the general formula (I)   and their pharmaceutically acceptable acid-additive salts and stereochemical isomeric forms where dotted line is optionally linkage; X is oxygen atom; R 1  and R 2  each means independently hydrogen or halogen atom; R 3  and R 4  each means independently hydrogen or halogen atom; R 5  means hydrogen, halogen atom or radical of the formula -O-R 10  (a-1) or N-R 11 R 12  (a-3) where R 10 , R 11 , R 12  are hydrogen atom; R 6  means radical of the formula (b-1)   or (b-2)   where R 16  is hydrogen atom or phenyl; R 17  is hydrogen atom or C 1-6 -alkyl; R 7  is hydrogen atom or C 1-6 -alkyl under condition that dotted line is not a linkage; R 8  is hydrogen atom, C 1-6 -alkyl or Het 1 CH 2 ; R 9  is hydrogen atom;   is pyridinyl. Compounds of the general formula (I) show inhibitory effect on farnesyltransferase activity and can be used for preparing medicinal agents inhibiting proliferative diseases. Invention relates also to pharmaceutical composition based on compounds of the general formula (I) eliciting inhibitory effect on farnesyltransferase activity, to method for preparing this composition, to intermediate derivatives of quinazolinone of the general formula (IX)   and their acid-additive salts or stereochemical isomeric forms where n = 2 or 3 and R 1 , R 2 , R 3 , R 4 , R 9 , mean values indicated above, to method for preparing some compounds of the general formula (I) where R 6  is radical of the formula (b-2) and to method for preparing intermediate derivatives of quinazolinone of the general formula (IX) and their acid-additive salts or stereochemical isomeric forms. EFFECT: improved preparing method of compounds and composition, valuable medicinal and biochemical properties. 10 cl, 4 tbl, 15 ex
Pharmaceutical compositions comprising Nedd9 protein are provided. The pharmaceutical compositions may further comprise FAK protein. These compositions can be used for the treatment of neuronal damages and neurodegenerative diseases. Methods for treating neuronal damages or neurodegenerative diseases are also provided. The methods comprise administering a composition comprising Nedd9 protein. Furthermore, methods for differentiating neuronal cells are provided. The methods comprise introducing a gene encoding Nedd9 protein into neuronal cells and allowing the expression of the gene in the cells.
AIM: To explore the effectiveness of the Metawell programme on cardiometabolic risk factors in China, which combines meal replacement biscuits, a wireless scale, and a mobile phone application.
METHODS: In this two-arm, parallel-design randomized study, 220 participants were randomly assigned to an intervention (n = 110) and a control (n = 110) group. Participants in the intervention group were instructed to use meal replacement products and scales for weight loss and monitoring, whereas participants in the control group received printed materials containing a sample diet and face-to-face weight loss education at enrolment. The trial lasted 6 months, including a weight loss period in Months 1-3 and a weight maintenance period in Months 3-6. Generalized estimating equations were used to compare differences between the two groups.
RESULTS: The median (interquartile range) ages of the intervention and control groups were 32.00 (28.00, 39.00) years and 33.00 (28.25, 41.00) years, with body mass indices of 28.20 (26.30, 30.95) kg/m2 and 27.70 (26.02, 29.70) kg/m2, respectively. Participants in the intervention group experienced significantly greater decreases in waist circumference, hip circumference, triglycerides, total cholesterol: high-density lipoprotein cholesterol ratio, fasting blood glucose, fasting insulin, and homeostatic model assessment of insulin resistance index compared to the control group (p < 0.01). Among participants who did not regain weight during the maintenance period after weight loss, the reductions in systolic and diastolic blood pressure were significantly greater in the intervention group than in the control group (p < 0.05).
CONCLUSIONS: The Metawell programme of caloric restriction and remote monitoring can be adapted to overweight and obese people in China to reduce their cardiometabolic risk factors. Furthermore, there was a better improvement in blood pressure in participants who maintained the effects of weight loss.
The Placebo will be injected via syringe and contains 0.5ml (only first injection) or 2x0.5ml (second to fourth injection) of 0.9% sodium chloride (0.9% NaCl). Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
Two double-blinded, placebo-controlled studies of identical design were conducted in patients with CIC. CIC was defined as, on average, less than 3 SBMs per week (a SBM is a bowel movement occurring in the absence of laxative use) along with one or more of the following symptoms of constipation for at least 6 months prior to randomization: 1) very hard stools for at least a quarter of all bowel movements; 2) sensation of incomplete evacuation following at least a quarter of all bowel movements; and 3) straining with defecation at least a quarter of the time.

Following a 2-week baseline/washout period, a total of 479 patients (mean age 47 [range 20 to 81] years; 89% female; 81% Caucasian, 10% African American, 7% Hispanic, 2% Asian, 11% at least 65 years of age) were randomized and received lubiprostone 24 mcg twice daily or placebo twice daily for 4 weeks. The primary endpoint of the studies was SBM frequency. The studies demonstrated that patients treated with lubiprostone had a higher frequency of SBMs during Week 1 than the placebo patients. In both studies, results similar to those in Week 1 were also observed in Weeks 2, 3, and 4 of therapy (Table 6).

In both studies, lubiprostone demonstrated increases in the percentage of patients who experienced SBMs within the first 24 hours after administration when compared to placebo (57% vs. 37% in Study 1 and 63% vs. 32% in Study 2, respectively). Similarly, the time to first SBM was shorter for patients receiving lubiprostone than for those receiving placebo.

Signs and symptoms related to constipation, including abdominal bloating, abdominal discomfort, stool consistency, and straining, as well as constipation severity ratings, were also improved with lubiprostone versus placebo. The results were consistent in subpopulation analyses for gender, race, and elderly patients at least 65 years of age.

During a 7-week randomized withdrawal study, patients who received lubiprostone during a 4-week treatment period were then randomized to receive either placebo or to continue treatment with lubiprostone. In lubiprostone-treated patients randomized to placebo, SBM frequency rates returned toward baseline within 1 week and did not result in worsening compared to baseline. Patients who continued on lubiprostone maintained their response to therapy over the additional 3 weeks of treatment.
This invention is directed toward non-pathogenic human immunodeficiency virus type 1 (HIV-1) strains containing deletions in the nef gene and U3 region of the long terminal repeat (LTR). A blood donor infected with HIV-1 and a cohort of six blood or blood product recipients infected from this donor were identified. These individuals, who remained free of HIV-1-related disease with stable and normal CD4+ lymphocyte counts 10 to 14 years after infection, were termed long-term nonprogressors (LTNPs). The molecular characterization of HIV-1 sequences obtained from either virus isolates or patient peripheral blood mononuclear cells (PBMCs) of LTNPs identified similar deletions in the nef gene and in the region of overlap of nef and the U3 region of the LTR. Full-length sequencing of one isolate genome and amplification of selected HIV-1 genome regions from other cohort members revealed no other abnormalities of obvious functional significance. These deletions corresponded to amino acids 166-206, or nucleotides 9281 to 9437, of the HIV-1NL43 nef/LTR region. These data illustrate the importance of nef or the U3 region of the LTR in determining the pathogenicity of HIV-1. These non-pathogenic strains should prove useful, inter alia, in the development of HIV-1-specific diagnostic reagents.
Systems and methods are provided for monitoring adherence to an insulin medicament dosage regimen for a subject. A data set comprising a plurality of metabolic events the subject engaged in within a period of time is obtained. Each respective metabolic event comprises a timestamp of the event and a characterization that is one of insulin regimen adherent and insulin regimen nonadherent. A plurality of primary adherence values is calculated, each respective adherence value representing a corresponding time window in a plurality of time windows within the period of time. Each time window is of a same first fixed duration. Each respective adherence value is computed by dividing a number of insulin regimen adherent events by a total number of events that have timestamps in the time window corresponding to the respective adherence value. The adherence values across the period of time are communicated thereby monitoring adherence to the insulin regimen.
A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. Tηε χελλ εν ιχημεντ μετηoδσ εμπλoψ εαγεντσ τηατ σπεχαλλψ εψoγνιζε Tηψ-1; ανδIΛ-7 Pα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.
OBJECTIVES: The aim of this study is to describe the incidence and demographics of laryngeal papillomatosis (LP) in Denmark, including sex and age distribution, recurrence rates, and HPV subtypes, using a new method of register identification.
METHODS: The data were extracted from the Danish Pathology Data Bank using SNOMED codes instead of the usual method using ICD codes from the Danish National Health Register. The derived pathology records were manually verified by three medical doctors. The study period was 1994-2021. Patients were categorized according to age as either juvenile-onset RRP (JoRRP) if <18 years or adult-onset RRP (AoRRP) if 18 years or older.
RESULTS: We identified 1819 RRP patients (JoRRP: 56; AoRRP:1763). The overall incidence per 100,000 inhabitants were 0.17 for JoRRP and 1.45 for AoRRP. The vast majority (72%) of the patients were male, but there was no significant difference in age at onset of RRP or recurrence rates between the sexes. Children below 3 years of age had the highest recurrence probability. Extracting data using SNOMED codes resulted in a positive predictive value of 99% regarding total number of biopsies and 98% regarding individuals. The incidence decreased throughout the study period.
CONCLUSION: Comparable incidence and recurrence rates of RRP were found between Denmark and Norway. In this study, the Danish Pathology Register was found to be a highly valuable method for identifying LP patients. The effect of the nationwide HPV vaccination program can be evaluated using this method as the vaccinated cohort is starting to grow older and reproduce.
LEVEL OF EVIDENCE: Retrospective registry-based national cohort study, 3 Laryngoscope, 134:5047-5053, 2024.
The present invention relates to traditional Chinese medicine for treating coronary disease, angina pectoris, myocardial infarction and ischemic heart disease. The present invention is composed of lignum dalbergiae odoriferae, red sage root, raw cattail pollen, red peony root, chuanxiong rhizome, kruakaen, fructus trichosanthis Mongolian snakegourd, xieba, notoginseng, sandalwood, cowherb seed, pilose asiabell root, coptis, gadfly, pinellia tuber, aurantii, rhizoma corydalis, curcuma root, nutagrass flatsedge rhizome, hairy holly root, licorice root, etc. The traditional Chinese medicine is soaked in hot water for 30 minutes, and then is put in a container to be infused by adding water. After boiled, the traditional Chinese medicine is continuously infused for 30 minutes by middle fire. A filtration solution is obtained after filtering and forms the traditional Chinese medicine 'yijining for coronary disease' of the present invention. An effective rate of the present invention reaches more than 97%.
The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.